Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as the pharmaceutical giants fight for (…)
Site référencé:
The Guardian
5600.jpg?width=140&quality=85&auto=format&fit=max&s=3c9fbe44095ac082c7d3ab69690c3997, 5600.jpg?width=460&quality=85&auto=format&fit=max&s=cfb59dc39e88893fa40a3c4f100554b7, 5600.jpg?width=700&quality=85&auto=format&fit=max&s=a68123dfb611648b76cc65a9b7551f47
The Guardian
Anna von Hausswolff : Iconoclasts review – exhilarating, euphoric goth songcraft
30/10/2025
England at risk of 2027 World Cup embarrassment and in need of ODI upswing
30/10/2025
A single match cost me thousands of dollars at 2026’s World Cup of the 1% | Leander Schaerlaeckens
30/10/2025
German dentists hold memorial recognising sadistic practices of profession under Nazis
30/10/2025
Tories will not deport legally settled people, Badenoch clarifies
30/10/2025
This isn’t a real ceasefire in Gaza – it’s a holding pattern before war returns | Sanam Vakil
30/10/2025